Ads by Google
PARI Pharma's eFlow electronic nebulizer was included in Gilead's recent NDA submittal to FDA for marketing approval of aztreonam lysine for inhalation.
New York Times examined the so-called doughnut hole coverage gap of the Medicare prescription drug benefit.
A groundbreaking joint project between the Ugandan pharmaceutical importer Quality Chemical Industries and Indian pharmaceutical company Cipla to produce generic antiretroviral drugs.
India's National AIDS Control Organization plans to provide about 5,000 HIV-positive people with access to second-line antiretroviral drugs.
FDA is evaluating postmarketing adverse event reports for Chantix (varenicline), a prescription medicine to help adults stop smoking.
E-prescribing for Medicare is just the beginning of the modernization and digitization our ailing health care system urgently needs.
Nora Dowd Eisenhower urged older adults and other Medicare beneficiaries to attend local enrollment meetings designed to help them choose a federal Medicare Part D prescription plan.
HIV-positive people with low health-literacy levels are less likely to understand their medication instructions and, therefore, are less compliant with their antiretroviral treatment regimens.
HIV-positive people with low health-literacy levels are less likely to understand their medication instructions and, therefore, are less compliant with their antiretroviral treatment regimens.
MAPRx are urging all Medicare Rx beneficiaries to closely examine changes to their Medicare prescription drug plans during open enrollment.
CMS will propose electronic prescribing standards for Medicare beneficiaries.
To help seniors make smarter decisions about Medicare Part D prescription drug plans during the open enrollment period which begins today, MedicareDrugPlans.com has released its top five tips.
FDA is on track to grant marketing approval to 18 or fewer new drugs in 2007, and pipelines are not looking better in the coming years.
Previous work has shown that, when a drug study was funded by the company that made that drug, the results might be biased in favour of that drug because the methods or analyses were manipulated.
Open Enrollment for 2008 for Medicare Part D Prescription Drug Coverage and Medicare Advantage Plans Begins Today
CMS has established a new online tool to help with the comparison of Medicare prescription drug plans.
Improvita Health Products has rolled out Fasprin, a patented, 81 milligram aspirin tablet that dissolves rapidly in the mouth instead of in the stomach.
FDA has granted tentative approval for Caraco Pharmaceutical Laboratories's Abbreviated New Drug Application for Lamotrigine Tablets.
Genzyme Corp. has received a letter from FDA requesting additional analyses and data regarding the marketing application for Synvisc-One in the United States. The company now expects that approval of the next-generation Synvisc (hylan G-F 20) to be delayed in the U.S. until at least the second half of 2008.
Although generic drugs produced in Brazil often are more expensive than similar drugs produced in other countries, Brazil still offers lower prices for patented antiretrovirals than other developing countries.
Legislation that would prevent brand-name drug companies from paying generic drug makers to delay market entry of generic medications has stalled in Congress in the face of major lobbying by the drug industry.
Abbott has received FDA approval to market and sell a lower-dose version of its antiretroviral drug Kaletra for children.
Cephalon has submitted a supplemental New Drug Application to FDA seeking approval to market FENTORA for the management of breakthrough pain in opioid tolerant patients.
GeoPharma has received an approval from the FDA to begin producing Carprofen.
The open enrollment period for the Medicare Part D prescription drug benefit begins Thursday and continues through the end of the year.
To Select the Best Medicare Prescription Drug Plan Seniors Need Help from Their Web-Savvy Boomer Children.
Medicare Part D beneficiaries shopping during open enrollment could be in for a nasty scare, with up to $1,915 in cost increases in 2008 for premiums and five commonly used prescriptions.
COA formally requested that the CMS reconsider its decision to restrict the access of senior cancer patients to vital anemia-fighting drugs.
When over- the-counter naproxen sodium was added to an aspirin therapy regimen, there was no change in platelet aggregation measures versus baseline.
FDA approved revised boxed warnings and other safety-related product labeling changes for erythropoiesis-stimulating agents (ESAs).